Evolving perspectives on clopidogrel in the treatment of ischemic stroke

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 4, 2006, Pages 245-248

  Gorelick, Philip ^a,e   Sechenova, Oksana ^b   Hennekens, Charles H ^c,d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Bethesda Hospital   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antiplatelet therapy; Aspirin; CHARISMA; Clopidogrel; Ischemic stroke; MATCH

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

BLEEDING; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DRUG HYPERSENSITIVITY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK; STROKE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ASPIRIN; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RESEARCH DESIGN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33845655657     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406296862     Document Type: Review

References (11)

1. American Heart Association. Heart disease and stroke statistics - 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 ; 113: e85 - e151.
2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Cosponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke. 2006 ; 37: 577-617.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324: 71-86.
4. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364: 331-337.
5. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354: 1706-1717.
6. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004 ; 148: 263-268.
7. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med. 2006 ; 354: 1744-1746.
8. Hennekens CH, Buring JE. Epidemiology in Medicine Boston: Little, Brown, and Company ; 1987.
9. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med. 2006 ; 354: 1667-1669.
10. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 ; 143: 1-13.
11. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 ; 367: 1665-1673.